Spire Healthcare Group (LON:SPI) Earns Buy Rating from Berenberg Bank

Spire Healthcare Group (LON:SPI)‘s stock had its “buy” rating reissued by Berenberg Bank in a report issued on Thursday, Marketbeat Ratings reports. They currently have a GBX 280 ($3.72) price target on the stock. Berenberg Bank’s price objective would suggest a potential upside of 32.70% from the stock’s current price.

Spire Healthcare Group Price Performance

Shares of SPI stock opened at GBX 211 ($2.80) on Thursday. Spire Healthcare Group has a 52-week low of GBX 168.20 ($2.23) and a 52-week high of GBX 260.50 ($3.46). The stock has a market cap of £847.31 million, a PE ratio of 30.03, a PEG ratio of 1.06 and a beta of 0.96. The company has a debt-to-equity ratio of 62.25, a quick ratio of 0.74 and a current ratio of 0.70. The firm’s 50 day moving average price is GBX 215.36 and its two-hundred day moving average price is GBX 206.84.

Spire Healthcare Group (LON:SPI) last announced its quarterly earnings data on Thursday, July 31st. The company reported GBX 4.10 ($0.05) earnings per share (EPS) for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. As a group, analysts forecast that Spire Healthcare Group will post 15.6634747 EPS for the current year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.